Top

Published in:

Open Access 01-07-2012 | Poster presentation

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India

Authors: Sujata Sawhney, Manjari Aggarwal

Published in: Pediatric Rheumatology | Special Issue 1/2012

Excerpt

Systemic onset JIA (SJIA) is a common subcategory of JIA in India and often difficult to treat. Tocilizumab (Actemra), an IL 6 blocker has been shown to be effective in children with SJIA. The drug is available in India for over a year. We have a high burden of infectious diseases here and biologics are therefore used judiciously. We used the drug in SJIA patients to test the efficacy, tolerability and side effect profile. …

Title: Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
Authors: Sujata Sawhney
Manjari Aggarwal
Publication date: 01-07-2012
Publisher: BioMed Central
Published in: Pediatric Rheumatology / Issue Special Issue 1/2012
Electronic ISSN: 1546-0096
DOI: https://doi.org/10.1186/1546-0096-10-S1-A49

At a glance: The STEP trials

Springer Medicine

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Acute respiratory infections, influenza-like illness and JIA: impact on disease activity and response to the influenza vaccine

Clinical characteristics of children with juvenile dermatomyositis recruited within the first 7 months of the CARRAnet registry

Hypergammaglobulinemia in the pediatric population

Informatics methodology for the rapid, validated development of clinical research forms in CARRAnet: incorporating user-centered design into the Delphi technique

Cartilage-protective effects of C-type natriuretic peptide over expression in K/BxN TCR arthritis model

IL-10 is a critical negative regulator of macrophage activation syndrome